Development of monoclonal and polyclonal antibodies
Statens Serum Instititut (SSI) has about 35 years of experience in developing and producing monoclonal antibodies and more than 100 years of experience in production of polyclonal antibodies. SSI uses different species of animals for this purpose.
SSI offers contract development of monoclonal antibodies against virtually any possible antigen of a customer’s preference. Establishing a monoclonal antibody-producing cell line (hybridoma) will allow the customer an indefinite and reliable supply of a well-defined and reproducible antibody for research or other similar uses.
Development of a polyclonal antibody is a process of about 3 months. Contrary to monoclonal antibodies, polyclonal antibodies contain a mixture of many different and undefined antibodies. Polyclonal antibodies can only be reproduced by immunizing new animals.
Our services include all tasks from antigen purification, characterization and derivatization to production of purified, characterized and quality controlled monoclonal or polyclonal antibody. Projects are carried out using our expertise in the fields of
- Protein Chemistry
- Antigen Conjugation
- Vaccine Preparation
- ELISA and other immunoassays
- Assay Development
- Cell Fusion
- Antibody Purification and Conjugation
Customers interested in having a monoclonal antibody developed by SSI, will be consulted in the planning phase to secure that development and production are in optimal accordance with the demands and expectations of the customer.
SSI enters individual contracts with every customer to ensure that every aspect of obligations and rights are defined from the beginning of the project.